Free Trial

Royalty Pharma (RPRX) Competitors

Royalty Pharma logo
$36.42 -0.17 (-0.45%)
As of 11:32 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

RPRX vs. ZTS, CORT, JAZZ, PRGO, SUPN, PCRX, NKTR, OMER, ASMB, and CPIX

Should you be buying Royalty Pharma stock or one of its competitors? The main competitors of Royalty Pharma include Zoetis (ZTS), Corcept Therapeutics (CORT), Jazz Pharmaceuticals (JAZZ), Perrigo (PRGO), Supernus Pharmaceuticals (SUPN), Pacira BioSciences (PCRX), Nektar Therapeutics (NKTR), Omeros (OMER), Assembly Biosciences (ASMB), and Cumberland Pharmaceuticals (CPIX). These companies are all part of the "pharmaceuticals" industry.

Royalty Pharma vs. Its Competitors

Royalty Pharma (NASDAQ:RPRX) and Zoetis (NYSE:ZTS) are both large-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, valuation, dividends, institutional ownership, analyst recommendations, risk, profitability and earnings.

Royalty Pharma has a net margin of 48.23% compared to Zoetis' net margin of 27.12%. Zoetis' return on equity of 55.48% beat Royalty Pharma's return on equity.

Company Net Margins Return on Equity Return on Assets
Royalty Pharma48.23% 24.71% 13.87%
Zoetis 27.12%55.48%19.14%

Royalty Pharma presently has a consensus price target of $49.00, indicating a potential upside of 34.38%. Zoetis has a consensus price target of $204.63, indicating a potential upside of 35.04%. Given Zoetis' higher probable upside, analysts clearly believe Zoetis is more favorable than Royalty Pharma.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Royalty Pharma
0 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
1 Strong Buy rating(s)
3.25
Zoetis
0 Sell rating(s)
4 Hold rating(s)
5 Buy rating(s)
1 Strong Buy rating(s)
2.70

In the previous week, Zoetis had 38 more articles in the media than Royalty Pharma. MarketBeat recorded 48 mentions for Zoetis and 10 mentions for Royalty Pharma. Zoetis' average media sentiment score of 1.26 beat Royalty Pharma's score of 1.16 indicating that Zoetis is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Royalty Pharma
6 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Positive
Zoetis
34 Very Positive mention(s)
2 Positive mention(s)
4 Neutral mention(s)
2 Negative mention(s)
0 Very Negative mention(s)
Positive

54.4% of Royalty Pharma shares are owned by institutional investors. Comparatively, 92.8% of Zoetis shares are owned by institutional investors. 18.9% of Royalty Pharma shares are owned by insiders. Comparatively, 0.2% of Zoetis shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Royalty Pharma has a beta of 0.5, meaning that its stock price is 50% less volatile than the S&P 500. Comparatively, Zoetis has a beta of 0.91, meaning that its stock price is 9% less volatile than the S&P 500.

Royalty Pharma pays an annual dividend of $0.88 per share and has a dividend yield of 2.4%. Zoetis pays an annual dividend of $2.00 per share and has a dividend yield of 1.3%. Royalty Pharma pays out 47.6% of its earnings in the form of a dividend. Zoetis pays out 35.9% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Royalty Pharma has increased its dividend for 5 consecutive years and Zoetis has increased its dividend for 14 consecutive years.

Zoetis has higher revenue and earnings than Royalty Pharma. Royalty Pharma is trading at a lower price-to-earnings ratio than Zoetis, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Royalty Pharma$2.26B9.06$858.98M$1.8519.71
Zoetis$9.26B7.29$2.49B$5.5727.20

Summary

Zoetis beats Royalty Pharma on 14 of the 19 factors compared between the two stocks.

Get Royalty Pharma News Delivered to You Automatically

Sign up to receive the latest news and ratings for RPRX and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding RPRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

RPRX vs. The Competition

MetricRoyalty PharmaMED IndustryMedical SectorNASDAQ Exchange
Market Cap$20.49B$3.04B$5.71B$9.50B
Dividend Yield2.44%2.40%4.60%3.99%
P/E Ratio19.7020.8727.8819.97
Price / Sales9.06324.50452.35101.58
Price / Cash8.5843.2336.5558.97
Price / Book2.088.328.635.89
Net Income$858.98M-$55.19M$3.24B$258.50M
7 Day Performance2.46%5.61%3.90%2.07%
1 Month Performance1.55%17.39%10.47%12.39%
1 Year Performance27.14%4.47%34.29%19.25%

Royalty Pharma Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
RPRX
Royalty Pharma
4.9729 of 5 stars
$36.42
-0.5%
$49.00
+34.5%
+27.6%$20.50B$2.26B19.7180Positive News
Dividend Announcement
Analyst Forecast
ZTS
Zoetis
4.9661 of 5 stars
$155.68
+0.5%
$212.13
+36.3%
-14.9%$69.31B$9.26B27.9513,800Positive News
CORT
Corcept Therapeutics
4.8281 of 5 stars
$72.77
+1.2%
$138.25
+90.0%
+96.0%$7.72B$675.04M62.73300
JAZZ
Jazz Pharmaceuticals
4.8546 of 5 stars
$111.44
+1.1%
$184.00
+65.1%
+8.5%$6.74B$4.06B14.862,800Analyst Forecast
PRGO
Perrigo
4.6382 of 5 stars
$27.42
-0.4%
$33.00
+20.4%
+0.7%$3.77B$4.37B-20.938,379News Coverage
Positive News
SUPN
Supernus Pharmaceuticals
1.7262 of 5 stars
$33.96
+2.5%
$36.00
+6.0%
+7.9%$1.90B$661.82M30.59580
PCRX
Pacira BioSciences
3.2941 of 5 stars
$23.31
+1.8%
$26.44
+13.4%
+7.7%$1.08B$700.97M-10.22720News Coverage
Upcoming Earnings
Analyst Upgrade
NKTR
Nektar Therapeutics
3.9947 of 5 stars
$24.41
-2.4%
$88.33
+261.9%
+16.2%$302.86M$87.25M-2.54220
OMER
Omeros
3.8451 of 5 stars
$3.93
+7.7%
$18.00
+358.0%
-34.1%$230.26MN/A-1.48210News Coverage
Positive News
Options Volume
Analyst Revision
Gap Up
ASMB
Assembly Biosciences
3.7745 of 5 stars
$18.84
+0.5%
$33.00
+75.2%
+24.0%$143.90M$32.15M-3.02100
CPIX
Cumberland Pharmaceuticals
0.9242 of 5 stars
$3.40
+13.3%
N/A+125.5%$50.87M$41.08M-13.6080Gap Up

Related Companies and Tools


This page (NASDAQ:RPRX) was last updated on 7/25/2025 by MarketBeat.com Staff
From Our Partners